Douglas J Swirsky - Net Worth and Insider Trading
Douglas J Swirsky Net Worth
The estimated net worth of Douglas J Swirsky is at least $189,939 dollars as of 2024-12-28. Douglas J Swirsky is the President & CEO of Genvec Inc and owns about 25,250 shares of Genvec Inc (GNVC) stock worth over $181,623. Douglas J Swirsky is the President and CEO of Rexahn Pharmaceuticals Inc and owns about 1,042 shares of Rexahn Pharmaceuticals Inc (REXN) stock worth over $7,544. Douglas J Swirsky is also the Director of Cellectar Biosciences Inc and owns about 2,500 shares of Cellectar Biosciences Inc (CLRB) stock worth over $772. Details can be seen in Douglas J Swirsky's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Douglas J Swirsky has not made any transactions after 2021-09-14 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Douglas J Swirsky
Douglas J Swirsky Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Douglas J Swirsky owns 8 companies in total, including MetaVia Inc (MTVA) , Cellectar Biosciences Inc (CLRB) , and Fibrocell Science Inc (FCSC) among others .
Click here to see the complete history of Douglas J Swirsky’s form 4 insider trades.
Insider Ownership Summary of Douglas J Swirsky
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| MTVA | MetaVia Inc | 2020-09-01 | director |
| CLRB | Cellectar Biosciences Inc | 2021-09-14 | director |
| FCSC | Fibrocell Science Inc | 2019-12-13 | director |
 | | 2019-01-29 | director & President and CEO |
| | 2018-05-22 | director |
| | 2017-06-16 | director & President and CEO |
| | 2018-01-02 | President and CFO |
| | 2023-03-27 | Chief Financial Officer |
Douglas J Swirsky Latest Holdings Summary
Douglas J Swirsky currently owns a total of 3 stocks. Among these stocks, Douglas J Swirsky owns 25,250 shares of Genvec Inc (GNVC) as of September 16, 2016, with a value of $181,623 and a weighting of 95.62%. Douglas J Swirsky owns 1,042 shares of Rexahn Pharmaceuticals Inc (REXN) as of January 29, 2019, with a value of $7,544 and a weighting of 3.97%. Douglas J Swirsky also owns 2,500 shares of Cellectar Biosciences Inc (CLRB) as of September 14, 2021, with a value of $772 and a weighting of 0.41%.
Latest Holdings of Douglas J Swirsky
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| GNVC | Genvec Inc | 2016-09-16 | 25,250 | 7.19 | 181,623 |
| REXN | Rexahn Pharmaceuticals Inc | 2019-01-29 | 1,042 | 7.24 | 7,544 |
| CLRB | Cellectar Biosciences Inc | 2021-09-14 | 2,500 | 0.31 | 772 |
Holding Weightings of Douglas J Swirsky
Douglas J Swirsky Form 4 Trading Tracker
According to the SEC Form 4 filings, Douglas J Swirsky has made a total of 0 transactions in Genvec Inc (GNVC) over the past 5 years. The most-recent trade in Genvec Inc is the acquisition of 1,000 shares on September 16, 2016, which cost Douglas J Swirsky around $5,000.
According to the SEC Form 4 filings, Douglas J Swirsky has made a total of 0 transactions in Rexahn Pharmaceuticals Inc (REXN) over the past 5 years. The most-recent trade in Rexahn Pharmaceuticals Inc is the acquisition of 1,042 shares on January 29, 2019, which cost Douglas J Swirsky around $31,500.
According to the SEC Form 4 filings, Douglas J Swirsky has made a total of 1 transactions in Cellectar Biosciences Inc (CLRB) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Cellectar Biosciences Inc is the acquisition of 2,500 shares on September 14, 2021, which cost Douglas J Swirsky around $26,000.
Insider Trading History of Douglas J Swirsky
- 1
Douglas J Swirsky Trading Performance
GuruFocus tracks the stock performance after each of Douglas J Swirsky's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Douglas J Swirsky is -18.64%. GuruFocus also compares Douglas J Swirsky's trading performance to market benchmark return within the same time period. The performance of stocks bought by Douglas J Swirsky within 3 months outperforms 3 times out of 10 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Douglas J Swirsky's insider trading performs compared to the benchmark.
Performance of Douglas J Swirsky
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -9.04 | | | | | |
| Relative Return to S&P 500(%) | -10.73 | | | | | |
Douglas J Swirsky Ownership Network
Douglas J Swirsky Owned Company Details
What does MetaVia Inc do?
Who are the key executives at MetaVia Inc?
Douglas J Swirsky is the director of MetaVia Inc. Other key executives at MetaVia Inc include 10 percent owner Dong-a St Co., Ltd , Acting Chief Financial Officer Marshall H Woodworth , and Interim CEO and President Joseph Hooker .
MetaVia Inc (MTVA) Insider Trades Summary
Over the past 18 months, Douglas J Swirsky made no insider transaction in MetaVia Inc (MTVA). Other recent insider transactions involving MetaVia Inc (MTVA) include a net purchase of 5,088,653 shares made by Dong-a St Co., Ltd ,
In summary, during the past 3 months, insiders sold 0 shares of MetaVia Inc (MTVA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 407 shares of MetaVia Inc (MTVA) were sold and 5,089,060 shares were bought by its insiders, resulting in a net purchase of 5,088,653 shares.
MetaVia Inc (MTVA)'s detailed insider trading history can be found in Insider Trading Tracker table.
MetaVia Inc Insider Transactions
Douglas J Swirsky Mailing Address
Above is the net worth, insider trading, and ownership report for Douglas J Swirsky. You might contact Douglas J Swirsky via mailing address: C/o Rexahn Pharmaceuticals, Inc., 15245 Shady Grove Road Suite 455, Rockville Md 20850.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
